Overview
ARQT market data
Price History
ARQT price chart
Valuation & Profitability
- P/E (TTM)
- 113.86 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.13 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.58 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 6.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.08 – $31.77 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.2B · P/B 18.77 · P/S 7.00.
Company News
Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38Benzinga · Aug 6, 2026, 5:19 PM
Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $38Benzinga · Aug 6, 2026, 1:28 PM
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate ProfitabilityThe Motley Fool · Aug 6, 2026, 1:01 PM
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results. Also, Needham raised its price target on the stock from $36 to $40.Benzinga · Aug 6, 2026, 12:25 PM
Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40Benzinga · Aug 6, 2026, 11:31 AM
Arcutis Biotherapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.Benzinga · Aug 5, 2026, 8:50 PM
8-K filing — Arcutis Biotherapeutics, Inc. (ARQT)SEC EDGAR · Aug 5, 2026, 8:14 PM
Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M EstimateBenzinga · Aug 5, 2026, 8:00 PM
Arcutis Expands Board of Directors with Appointment of Chris PeetzGlobenewswire Inc · Jul 16, 2026, 1:15 PM
FDA Accepts Supplemental New Drug Application For Arcutis Biotherapeutics' ZORYVE Cream 0.05%Benzinga · Jul 8, 2026, 12:05 PM